Production (Stage)
GT Biopharma, Inc.
GTBP
$3.04
$0.020.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.09M | 8.57M | 8.54M | 8.01M | 7.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.21M | 14.36M | 13.77M | 13.29M | 13.00M |
| Operating Income | -13.21M | -14.36M | -13.77M | -13.29M | -13.00M |
| Income Before Tax | -11.67M | -13.16M | -12.35M | -11.35M | -9.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.67 | -13.16 | -12.35 | -11.35 | -9.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.67M | -13.16M | -12.35M | -11.35M | -9.64M |
| EBIT | -13.21M | -14.36M | -13.77M | -13.29M | -13.00M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -5.70 | -7.01 | -7.48 | -7.72 | -7.04 |
| Normalized Basic EPS | -3.83 | -4.38 | -4.68 | -4.83 | -4.41 |
| EPS Diluted | -5.70 | -7.01 | -7.48 | -7.72 | -7.04 |
| Normalized Diluted EPS | -3.83 | -4.38 | -4.68 | -4.83 | -4.41 |
| Average Basic Shares Outstanding | 8.55M | 7.58M | 6.71M | 5.84M | 5.47M |
| Average Diluted Shares Outstanding | 8.55M | 7.58M | 6.71M | 5.84M | 5.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |